StockData
AEON Biopharma, Inc. logo

AEON Biopharma, Inc. (AEON) stock

AEONNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026Score 4/30
$0.15−0.01 (-3.59%)

Close on Nov 13, 2026Market cap $7.63MP/E –Yield –

Earnings

AEON Biopharma's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
Nov 13, 2026
Q3 FY2026 · estimated, before the open
Revenue, Q4 FY2023
–
EPS, Q4 FY2023
-$0.71
Latest guidance
None
No outlook given in releases

Quarterly results

Revenue and earnings per share from each of AEON Biopharma's earnings releases, newest first

QuarterReportedRevenueYoYEPSSource
Q3 FY2026ended Sep 30, 2026Nov 13, 2026Expected––––
Q2 FY2026ended Jun 30, 2026Aug 12, 2026after the close–––Release
Q1 FY2026ended Mar 31, 2026May 14, 2026after the close–––Release
Q4 FY2025ended Dec 31, 2025Mar 30, 2026after the close–––Release
Q3 FY2025ended Sep 30, 2025Nov 14, 2025before the open–––Release
Q2 FY2025ended Jun 30, 2025Aug 12, 2025after the close–––Release
Q1 FY2025ended Mar 31, 2025May 14, 2025after the close–––Release
Q4 FY2024ended Dec 31, 2024Mar 24, 2025after the close–––Release
Q3 FY2024ended Sep 30, 2024Nov 13, 2024after the close–––Release
Q2 FY2024ended Jun 30, 2024Aug 12, 2024after the close–––Release
Q1 FY2024ended Mar 31, 2024May 14, 2024after the close–––Release
Q4 FY2023ended Dec 31, 2023Mar 29, 2024during market hours––-$0.71Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Guidance

AEON Biopharma has not given guidance in its releases

Many companies give their outlook only on the conference call or not at all. When AEON Biopharma puts a forecast in an earnings release, it is listed here with the exact sentence.

Press releases

Releases AEON Biopharma filed with the SEC as exhibits to Form 8-K or 6-K

  1. market dominated by a single brand
    Update
  2. AEON Biopharma FDA Type 2b Meeting Feedback Clarifies Biosimilar Development Plan for ABP-450
    Update
  3. AEON Biopharma Reports Second Quarter 2026 Financial Results and Provides Corporate Update
    Results
  4. market dominated by a single brand
    Results
  5. AEON Biopharma Regains Compliance with NYSE American Continued Listing Standards
    Update
  6. AEON Biopharma Announces Pricing Of Upsized $13.75 Million Public Offering with Accompanying Milestone Warrants Providing Potential for Additional Future Funding
    News
  7. market dominated by a single brand
    Update
  8. AEON Biopharma Reports First Quarter 2026 Financial Results and Provides Corporate Update
    Results
  9. AEON Biopharma Reports Full Year 2025 Financial Results and Highlights Positive Comparative Analytical Results and FDA Feedback for ABP-450 Biosimilar Program
    Results
  10. AEON Biopharma Reports BPD Type 2a Meeting with FDA and Shareholder Approval of the November Transactions
    Update
  11. Bringing Biosimilar Competition to a
    Update
  12. AEON Biopharma Announces Execution of Exchange Agreement with Daewoong
    Update
  13. Fresh Data | New Capital | Simplified Structure –
    Update
  14. AEON Biopharma Reports Third Quarter 2025 Results, Including Positive ABP-450 Biosimilarity Data and Strategic Positioning for Continued Growth
    Results
  15. Accelerated Access to the $3B+
    Update

See a number that looks wrong?